Literature DB >> 1721059

Localization of an apolipoprotein A-I epitope critical for activation of lecithin-cholesterol acyltransferase.

C L Banka1, D J Bonnet, A S Black, R S Smith, L K Curtiss.   

Abstract

Apolipoprotein (apo) A-I, the major apoprotein of human high density lipoprotein, is a vital cofactor for lecithin-cholesterol acyltransferase (LCAT), the plasma enzyme responsible for esterification of free cholesterol associated with high density lipoprotein. This esterification is an important component of the reverse cholesterol transport process. An immunochemical approach was used to test the hypothesis that a discrete region of apoA-I was important for LCAT activation. Three human apoA-I-specific monoclonal antibodies were found to inhibit LCAT activation in vitro in a manner directly proportional to their ability to bind to apoA-I-proteoliposomes in fluid phase immunoassays. This relationship was not observed with another four apoA-I-specific antibodies that also were able to bind to the apoA-I proteoliposomes. The use of synthetic peptides representing short amino acid sequences of the apoA-I molecule facilitated the identification of discrete but overlapping apoA-I epitopes for those antibodies that interfered with LCAT-mediated cholesterol esterification. These epitopes spanned amino acid residues 95-121 of mature apoA-I. Therefore, this region is most likely involved in the activation of LCAT by apoA-I.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1721059

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

1.  Cardiolipin is a normal component of human plasma lipoproteins.

Authors:  H Deguchi; J A Fernandez; T M Hackeng; C L Banka; J H Griffin
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

Review 2.  The antiphospholipid syndrome and atherosclerosis: clue to pathogenesis.

Authors:  Joan T Merrill
Journal:  Curr Rheumatol Rep       Date:  2003-10       Impact factor: 4.592

Review 3.  A novel amyloidogenic variant of apolipoprotein AI: implications for a conformational change leading to cardiomyopathy.

Authors:  M T Walsh
Journal:  Am J Pathol       Date:  1999-01       Impact factor: 4.307

4.  A thumbwheel mechanism for APOA1 activation of LCAT activity in HDL.

Authors:  Allison L Cooke; Jamie Morris; John T Melchior; Scott E Street; W Gray Jerome; Rong Huang; Andrew B Herr; Loren E Smith; Jere P Segrest; Alan T Remaley; Amy S Shah; Thomas B Thompson; W Sean Davidson
Journal:  J Lipid Res       Date:  2018-05-17       Impact factor: 5.922

5.  Apolipoprotein AI and transthyretin as components of amyloid fibrils in a kindred with apoAI Leu178His amyloidosis.

Authors:  M M de Sousa; C Vital; D Ostler; R Fernandes; J Pouget-Abadie; D Carles; M J Saraiva
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

6.  Arginine 123 of apolipoprotein A-I is essential for lecithin:cholesterol acyltransferase activity.

Authors:  Irina N Gorshkova; Xiaohu Mei; David Atkinson
Journal:  J Lipid Res       Date:  2017-12-05       Impact factor: 5.922

Review 7.  What causes the antiphospholipid syndrome?

Authors:  J T Merrill
Journal:  Curr Rheumatol Rep       Date:  2001-08       Impact factor: 4.592

8.  Effect of repeated apoA-IMilano/POPC infusion on lipids, (apo)lipoproteins, and serum cholesterol efflux capacity in cynomolgus monkeys.

Authors:  Herman J Kempen; Monica Gomaraschi; S Eralp Bellibas; Stephanie Plassmann; Brad Zerler; Heidi L Collins; Steven J Adelman; Laura Calabresi; Peter L J Wijngaard
Journal:  J Lipid Res       Date:  2013-07-04       Impact factor: 5.922

9.  Dynamics of activation of lecithin:cholesterol acyltransferase by apolipoprotein A-I.

Authors:  Martin K Jones; Andrea Catte; Ling Li; Jere P Segrest
Journal:  Biochemistry       Date:  2009-12-01       Impact factor: 3.162

10.  Altered epitope expression of human interstitial fluid apolipoprotein A-I reduces its ability to activate lecithin cholesterol acyl transferase.

Authors:  L Wong; L K Curtiss; J Huang; C J Mann; B Maldonado; P S Roheim
Journal:  J Clin Invest       Date:  1992-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.